NCT03508817.

Study name	Atropine 0.01% eye drops in myopia study (AIMS)
Methods	Randomized parallel‐group design
Participants	Inclusion criteria: age 6 to 15 years; myopia ≥ 2.00 D (cycloplegic refraction; spherical equivalent); no prior or current treatment for preventing myopia progression (bifocals / progressive addition lenses / orthokeratology) Exclusion criteria: best corrected visual acuity < 0.5 (6/12); refractive myopia; astigmatism ≥ 1.5 D; amblyopia; ocular hypertension / glaucoma; prior intraocular surgery; allergy to atropine eye drops; systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome; history of cardiac or significant respiratory diseases; lack of consent for participating in the study
Interventions	Intervention: atropine sulfate 0.01% eye drops Comparison intervention: control
Outcomes	Primary outcomes: spherical equivalent refractive error Secondary outcomes: axial length; adverse events Maximum follow‐up: 2 years
Starting date	December 2018 Estimated end date: January 2022
Contact information	https://clinicaltrials.gov/ct2/show/NCT03508817
Notes